193 related articles for article (PubMed ID: 28817605)
1. All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis.
Mei D; Lv B; Chen B; Xiao S; Jiang J; Xie Y; Jiang L
PLoS One; 2017; 12(8):e0182835. PubMed ID: 28817605
[TBL] [Abstract][Full Text] [Related]
2. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
[TBL] [Abstract][Full Text] [Related]
3. The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake.
Tuncel M; Aydin D; Yaman E; Tazebay UH; Güç D; Doğan AL; Taşbasan B; Uğur O
Cancer Biother Radiopharm; 2007 Jun; 22(3):443-9. PubMed ID: 17679169
[TBL] [Abstract][Full Text] [Related]
4. The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake.
Tuncel M; Aydin D; Yaman E; Tazebay UH; Güç D; Doğan AL; Taşbasan B; Uğur O
Cancer Biother Radiopharm; 2007 Apr; 22(2):281-8. PubMed ID: 17600477
[TBL] [Abstract][Full Text] [Related]
5. All-trans-retinoic acid promotes iodine uptake via up- regulating the sodium iodide symporter in medullary thyroid cancer stem cells.
Tang M; Hou YL; Kang QQ; Chen XY; Duan LQ; Shu J; Li SL; Hu XL; Peng ZP
Asian Pac J Cancer Prev; 2014; 15(4):1859-62. PubMed ID: 24641421
[TBL] [Abstract][Full Text] [Related]
6. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
7. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.
Ke CC; Liu RS; Yang AH; Liu CS; Chi CW; Tseng LM; Tsai YF; Ho JH; Lee CH; Lee OK
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):61-71. PubMed ID: 23081821
[TBL] [Abstract][Full Text] [Related]
8. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
10. Targeting the BRAF Signaling Pathway in CD133pos Cancer Stem Cells of Anaplastic Thyroid Carcinoma.
Bozorg-Ghalati F; Hedayati M; Dianatpour M; Mosaffa N; Azizi F
Asian Pac J Cancer Prev; 2019 May; 20(5):1353-1360. PubMed ID: 31127889
[TBL] [Abstract][Full Text] [Related]
11. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.
Elisei R; Vivaldi A; Agate L; Ciampi R; Molinaro E; Piampiani P; Romei C; Faviana P; Basolo F; Miccoli P; Capodanno A; Collecchi P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2005 Apr; 90(4):2403-11. PubMed ID: 15623821
[TBL] [Abstract][Full Text] [Related]
12. Role of CD44(high)/CD133(high) HCT-116 cells in the tumorigenesis of colon cancer.
Zhou JY; Chen M; Ma L; Wang X; Chen YG; Liu SL
Oncotarget; 2016 Feb; 7(7):7657-66. PubMed ID: 26840024
[TBL] [Abstract][Full Text] [Related]
13. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.
Chen XL; Chen XZ; Wang YG; He D; Lu ZH; Liu K; Zhang WH; Wang W; Li CC; Xue L; Zhao LY; Yang K; Liu JP; Zhou ZG; Hu JK; Mo XM
Oncotarget; 2016 Sep; 7(38):62049-62069. PubMed ID: 27557490
[TBL] [Abstract][Full Text] [Related]
15. Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells.
Nomura A; Dauer P; Gupta V; McGinn O; Arora N; Majumdar K; Uhlrich C; Dalluge J; Dudeja V; Saluja A; Banerjee S
Oncotarget; 2016 Aug; 7(35):56324-56337. PubMed ID: 27472388
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
17. Effect of all-trans retinoic acid on the proliferation and differentiation of brain tumor stem cells.
Niu CS; Li MW; Ni YF; Chen JM; Mei JM; Li J; Fu XM
J Exp Clin Cancer Res; 2010 Aug; 29(1):113. PubMed ID: 20716331
[TBL] [Abstract][Full Text] [Related]
18. MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133
Yang L; Li N; Yan Z; Li C; Zhao Z
J Mol Neurosci; 2018 Nov; 66(3):369-377. PubMed ID: 30267383
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
20. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]